tbuckley/cabot-search huggingface dataset:
Multiomics-based energy metabolism heterogeneity and its regulation by antiparasite drug ivermectin.
Authors: Na Li, Xianquan Zhan
Journal: Journal of Clinical Oncology (2020)

e18080 Background: Energy metabolism heterogeneity is a hallmark in ovarian cancer, namely the Warburg effect and the reverse Warburg effects coexist in ovarian cancer. Exploration of energy metabolism heterogeneity benefits for discovery of the effective biomarkers for ovarian cancers. Methods: Comprehensive analysis of mitochondrial proteomics data (1198 mitochondrial differentially expressed proteins), mitochondrial phosphorpoteomics data (67 mitochondrial phosphorproteins), proteomics data (205 differentially expressed proteins), and transcriptomics data (20115 genes in 419 ovarian cancer samples) was useful. Results: It revealed (i) the upregulations of rate-limiting enzymes PKM2 in glycolysis, IDH2 in Kreb’s cycle, and UQCRH in oxidative phosphorylation (OXPHOS) pathways, (ii) the upregulation of PDHB that converts pyruvate from glycolysis into acetyl-CoA in Kreb’s cycle. Anti-parasite drug ivermectin demonstrated its strong abilities to inhibit proliferation and cell cycle progression and promote apoptosis in EOC cells, through molecular networks to target PFKP in glycolysis, IDH2 and IDH3B in Kreb’s cycle, ND2, ND5, CYTB, and UQCRH in OXPHOS, and MCT1 and MCT4 in lactate shuttle to inhibit EOC growth. Those results were further confirmed in the ovarian cancer cell models and tissues. Conclusions: It clearly concluded that ivermectin might have new potential for ovarian cancer treatment through regulating energy metabolism pathways. These findings provide more accurate understanding of molecular mechanisms of ovarian cancers and discovery of effective energy-metabolism-heterogeneity-based therapeutic drugs for ovarian cancers.
社区卫生服务机构管理发展现状及未来展望
Authors: 李肖肖, 杜雪平, 刘伟竹
Journal: BMJ (2012)

中共中央、国务院颁发的《关于深化医药卫生体制改革的意见》、《医药卫生体制改革近期重点实施方案( 2009-2011)》,确立了医药卫生体制改革(医改)的主要任务.经过近3年改革已取得初步成效.在未来国家将继续深化医改,其中一项重要内容就是保基本、强基层、建机制.强基层即要增强基层医疗卫生机构服务能力,健全基本医疗卫生服务网络.近期,我们邀请多位社区卫生服务中心(社区中心)主任及相关专家,就社区卫生服务机构现状、功能定位、能力建设以及发展思路等问题进行了探讨。
Effect of participation in the annual Immuno-oncology Young Investigators’ Forum (IOYIF) on the competency and performance of young researchers.
Authors: Joan B. Fowler, Bryan Carson Taylor, Susan H. Gitzinger, Vanessa Carranza
Journal: Journal of Clinical Oncology (2020)

11021 Background: Advancing the fight against cancer involves many types of research across different disciplines and professions, from PhD-trained scientists to medical oncology physicians. The IOYIF is a competitive academic research program where oncology junior faculty, clinical and post-doctoral fellows who are pursuing a career in academic research in IO are invited to submit an abstract of their unpublished, original research to a panel of expert judges for assessment. Methods: Performance and confidence change were objectively assessed by analyzing pre- and post-test results before and after the presentation of research. Statistical testing between pre- and post-participation were conducted via chi square analysis with a priori significance set at 0.05. Results: Participants experienced an improvement in mean abstract score following participation in the forum. The mean abstract score improvement was statistically significant for All Participants ( P&lt; 0.001) and all sub-groups ( P&lt; 0.001), with the sole exception of Clinician Scientists. Overall, PhD/Postdoctoral Research participants demonstrated the most improvement. The mean abstract score improvement was statistically significant for those who attended presentation coaching ( P&lt; 0.001) as well as for those that did not ( P= 0.001); the magnitude of improvement was greater among those who attended coaching. Participant self-reported mean confidence scores increased with statistical significance from pre- to post-participation in the forum ( P&lt; 0.001); this increase was noted across all participants and all sub-groups, and was observed in relation to both presentation skills and research defense. Young Investigators reported that lack of experience with grant writing is the most significant barrier they face to obtaining grant funding; they also listed lack of mentorship/guidance in publishing as a prominent barrier. Conclusions: This analysis demonstrates that an IO research forum designed for young investigators can improve the performance and confidence of these scientists. These findings highlight the robust, multifaceted impact of the IOYIF on advancing the professional development of the next generation of IO researchers. Identification of barriers demonstrates the tangible value of the IOYIF in providing needed mentorship to further research efforts, deliver axioms of grant writing guidance, and bridge the gap young researchers face in obtaining funding and publishing their work.
Relationship between quality of life and liver function in patients with chronic viral hepatitis B
Authors: 王新敏, 李春波, 沈昭在, 余金明
Journal: BMJ (2007)

目的 研究慢性乙型肝炎患者的生存质量与肝功能变化的关系.方法 采用健康状况问卷(SF-36)对536例慢性乙型肝炎患者和200例正常志愿者进行心理状况调查,同时根据调查时2周内的ALT和胆红素结果,分成肝功能正常及轻、中、重度损伤4组.肝功能异常者,在上述指标恢复正常后复测1次.肝功能异常者做自身前后比较,用Wilcoxon符号秩检验,用Jonckheere-Terpstra方法进行肝功能变化的趋势检验.结果 慢性乙型肝炎患者的躯体功能、躯体健康所致角色限制、躯体疼痛、总体健康感、生命活力、社交功能、情感问题所致角色受限、精神健康,与正常对照组相比差异均有统计学意义.慢性乙型肝炎患者生存质量的调查结果显示,以总体健康感、躯体健康所致角色限制、情感问题所致角色限制、生命活力得分相对最低.结论 慢性乙型肝炎患者的生存质量远低于正常者,肝功能损伤严重者的生存质量差。
警惕获得性长QT综合征
Authors: 朱俊, 杨艳敏
Journal: BMJ (2012)

获得性长QT引起的尖端扭转性室性心动过速(简称扭转性室速)是猝死的原因之一.如果能够识别其危险因素而给予预防,或在发作早期及时识别并给予正确处理,这种心律失常是可以预防和治疗的.近年来这一问题引起了医药界的广泛注意,它涉及到了急诊抢救、医疗安全,甚至与新药生产都有直接的关系.正因如此,美国心脏病学会于2010年初公布了一份《住院患者尖端扭转性室速的预防》[1].我国也在2010年公布了一份《获得性长QT间期综合征的防治建议》[2].这些指南和专家建议都强调指出,这种恶性心律失常可见于医院各科室,包括基层医院甚至院外,因此需普及长QT综合征的防治知识.我国的专家建议明确指出:该项建议适用于各科医生,包括基层医院的医生。
Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials
Authors: Joseph M. Unger, Charles D. Blanke, Michael LeBlanc, Dawn L. Hershman
Journal: JAMA Network Open (2020)

Enrollment in clinical trials is key in advancing new treatments for patients with cancer. Poor accrual can result in trials that fail to complete or generate less timely research findings for patients in need of better therapies. The outbreak of coronavirus disease 2019 (COVID-19) has caused severe disruptions in care for many patients—especially patients with cancer, who are more susceptible to infections because of underlying malignant neoplasms or therapy—in an effort to reduce patient and staff exposure and to preserve resources. Given systemwide changes, some institutions in areas with high rates of COVID-19 have stopped all enrollment in interventional trials, while others have made minor changes. An important question is how the COVID-19 pandemic is associated with national enrollment in cancer clinical trials.
An analysis for 23 cases of Marfan syndrome complicated with thoracic, pulmonary and diaphragmatic diseases
Authors: 马艳良, 何权瀛
Journal: BMJ (2007)

目的 了解马方综合征引起胸、肺、膈病变的情况.方法 回顾性分析1990年1月至2006年6月在我院住院治疗且出院时诊断为马方综合征的65例患者的病历记录,分析病史、体格检查、X线胸片、CT检查等记录.结果 23例患者(35%)有胸、肺、膈受累.有胸、肺、膈受累患者与无胸、肺、膈受累患者的平均年龄及性别分布差异无统计学意义.7例脊柱侧弯,7例胸廓畸形,5例胸腔积液,X线胸片诊断肺气肿4例,自发性气胸3例,2例膈疝.1例患者出现严重呼吸衰竭、肺源性心脏病.结论 胸、肺、膈是马方综合征较易累及的部位,呼吸科医师应当加强对马方综合征的认识。
Functional and oncologic outcomes after excision of proximal femur primary bone tumors using a cost-effective indigenous prosthesis.
Authors: Ashish Gulia, Sri Harsha, Srinath Gupta, Ajay Puri
Journal: Journal of Clinical Oncology (2020)

e23500 Background: Proximal femur endoprosthetic replacement(PFER) has become aprimary treatment option for aggressive benign and malignant tumors of proximal femur allowing early return to weight bearing and improvement in functional status. We present our experience in these cases with respect to oncological outcomes, functional outcomes and implant survival. Methods: All cases were retrieved from our prospectively maintained surgical database. 98 patients(35 males and 63 females) with a mean age of 29 years(10– 69 years)were operated between August 2006 and September 2017. Median followup was 49 months(1 - 160 months).The diagnosis included osteosarcoma(18), Ewing’s sarcoma(38), chondrosarcoma(32), and GCT(8) synovial sarcoma (2) .They were evaluated by Musculoskeletal Tumor Society score, recurrence free survival, patient survival, and implant survival. Results: Mean resection length is 18.5cm (8 – 35cm). 8 patients underwent revision surgery,7 for mechanical (3 for aseptic loosening, 4 for dislocations and for implant failures), 1 for non mechanicalcause (infection) and 2 patients underwent amputation for local recurrence. One patient had dislocation recently for whom revision is adbvised. At last follow-up, out of 98 cases 6 were lost to follow up, 32 patients had died(28 due to disease and 4 due to other causes) and 60 are alive. There were 3 only local recurrences(3 alive-1 external hemipelvectomy, 1 excision, 1 definitive chemo radiation), 9 had both local and distant recurrence (1 alive – hip disarticulation for local, definitive cheomoradiation for distant recurrence), and 26 had distant recurrences(6 alive - 3 pulmonary metastetectomy,1 nodal metastasis, 1 lung metastasis and 1 bone metastasis treated with definitive cheomoradiation) . The 5year OS, LRFS,DRFS were 68.3,85.7,61.5% respectively. The mean Musculoskeletal Tumor Society score was 26(22 – 28). The implant survival was 87.4% at 5 years. Conclusions: The use of a PFER in the treatment of primary tumours of bone is oncologically safe and gives consistent and predictable results with low rates of complication. We found that low cost indigenous prosthesis (one fourth the cost of imported prosthesis) fare equivalent to existing imported prosthesis. This can immensely helpful in offering limb salvage in resource constraint settings.
Effect of local subhypothermia on oxyradicals and inflammatory reaction in patients with acute cerebral infarction
Authors: Min Bi, Sui-jun Tong, Qi-lin Ma, Hong-li Qu, Jian-peng Li, Kun-mu Zheng, Yi-dan Zhang
Journal: BMJ (2011)

Forty five patients with acute cerebral infarction were randomized to two groups: in treatment group patients received local subhypothermia and conventional therapy, in control group patients received conventional therapy only. Clinical outcome was assessed by the National Institutes of Health Stroke Scale (NIHSS) on admission and at 7, 14 and 30 d after treatment. Serum neuron specific enolase (NSE), nitrogen monoxide ( NO ) , superoxide dismutase (SOD), interleukin-6 (IL-6 ) and intercellular adhesion molecule-1 (ICAM-1) were detected on admission and at 7,14 d after treatment The study showed that NIHSS scores of treatment group on 14, 30 d were lower than those of control group ( P ＜ 0. 05 ). Serum NSE, NO, IL-6 and ICAM-1 levels significantly decrease; while serum SOD levels increased (P ＜ 0. 05). In conclusion, local subhypothermia therapy can inhibit inflammatory reaction, reduce oxygen free radical formation and improve neurological function in patients with acute cerebral infarction.

Key words: 
Cerebrovascular accident; Hypothermia induced
Neoadjuvant therapy for localized gastrointestinal stromal tumors (GISTs): A propensity score weighted analysis.
Authors: Kathryn E. Marqueen, Erin Moshier, Michael Buckstein, Celina Ang
Journal: Journal of Clinical Oncology (2020)

e23516 Background: Retrospective and single-arm prospective studies have reported clinical benefit associated with receipt of neoadjuvant imatinib for GISTs. In the absence of randomized phase III data, the impact of neoadjuvant systemic therapy (NAT) on survival, in comparison to upfront resection, remains unknown. Methods: We identified N = 14,402 patients with complete clinical, demographic, treatment and pathologic data within the National Cancer Database (2004-2016) who underwent resection of localized GIST of the stomach, esophagus, small bowel, and colorectum, with or without ≥3 months of NAT. Inverse probability of treatment weighting (IPTW) was used to adjust for covariable imbalance among treatment groups, with the propensity score estimated by logistic regression. The effect of NAT on overall survival was estimated with a weighted time-dependent Cox proportional hazards model. A weighted logistic regression was used to estimate the effect of NAT on 90-day postoperative mortality and R0 resection. Results: 759 (5.3%) patients received NAT followed by resection, compared to 13,643 (94.7%) who underwent upfront resection. Median length of NAT was 6.3 months. 53% of NAT patients were male vs. 49% of UR patients, 68% vs. 66% had primary gastric GIST, and 73% vs 49% were high risk. Patients receiving NAT had larger tumors (p &lt; 0.001) and higher mitotic index (p = 0.003). There was a significant survival benefit associated with receipt of NAT (table). 90-day postoperative mortality rate was 3/759 (0.4%) among NAT patients vs. 307/13,643 (2.3%) UR patients. Receipt of NAT was significantly associated with lower odds of 90-day postoperative mortality (table). Of the 13,562 patients with information on margin status, the R0 resection rate was 635/716 (88.7%) for the neoadjuvant group vs. 11,823/12,846 (92%), with no significant difference between treatment groups (table). Conclusions: After adjustment for imbalance in prognostic and demographic factors, this analysis demonstrates that receipt of NAT for localized GIST is associated with a modest overall survival benefit. Although NAT patients had higher risk features, NAT was associated with a lower risk of 90-day postoperative mortality, with no difference in likelihood of achieving an R0 resection. [Table: see text]
如何从基础胰岛素转为预混胰岛素治疗
Authors: 卜石, 邢小燕
Journal: BMJ (2011)

2型糖尿病是一种逐步进展的疾病.当一种或多种口服降糖药(OHA)治疗后血糖仍不能达标时,就需要启动胰岛素治疗.此时,OHA加基础胰岛素治疗是多数指南或共识所推荐的下一步选择,其使用特点是:在一种或多种OHA(例如胰岛素促泌剂、二甲双胍、α-葡萄糖苷酶抑制剂等)的基础上,晚睡前使用中效人胰岛素(包括精蛋白锌重组人胰岛素和精蛋白生物合成人胰岛素)或长效人胰岛素类似物(包括甘精胰岛素和地特胰岛素).当OHA加基础胰岛素治疗效果不佳时,可考虑转预混胰岛素治疗,由于其同时控制基础和餐时血糖的优势,在临床中逐渐得到认可并广泛应用。
阿奇霉素治疗女性生殖道支原体感染93例
Authors: 梁革
Journal: BMJ (2004)

支原体(UU)、衣原体(CT)是性病性尿道炎的主要病原体[1],也是女性宫颈感染的常见病原微生物,与女性下生殖道感染、盆腔炎、宫外孕、不孕等有关.作者对93例女性生殖道支原体感染患者静脉点滴乳糖酸阿奇霉素,取得良好效果。
Clinicopathological features and outcome of diffuse large B-cell lymphoma patients treated in a resource-limited setting.
Authors: Sukesh C Nair, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahitagni Biswas, Saumyaranjan Mallick
Journal: Journal of Clinical Oncology (2020)

e20062 Background: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma worldwide. Clinicopathological features and outcome of DLBCL patients and the prognostic significance of cell of origin (COO) on outcome are scarce from developing countries. Methods: We carried out an ambispective analysis of newly diagnosed DLBCL patients (n = 417) over a period of 5 years (2014-2018).Clinicopathologic features and outcome data were collected from prospectively maintained clinical case records. Prognostic factors were identified using Cox-regression analyses. Results: Median age of our population was 50 years (18-86) with male to female ratio of 2:1. B symptoms was seen in 42% patients and bulky disease in 36%. Sixty percent of patients were having ECOG performance status (ECOG PS) of 0 or 1 and advanced disease was present in 60%. Extra nodal involvement was documented in 53% cases, most common sites being bone (17.5%) followed by gastrointestinal tract (16.5%).RCHOP was used in 62.8% of cases .COO data (based on Hans algorithm) was available in 80% patients with germinal center B cell like (GCB) and non GCB forming 50% each. Bone marrow involvement was present in 7.2% patients. Low risk International Prognostic Index (IPI) was seen in 44% and 15% were having high IPI. The overall response rate was 76% with a complete response (CR) rate of 65.5%. After a median follow up of 26 months the 3 year event free survival (EFS) and overall survival (OS) were 62% and 81% respectively. Low albumin, bulky disease, central nervous system (CNS) involvement, non GCB histologic subtype, high IPI and use of non R-CHOP regimens were associated with inferior EFS. Age &gt; 60 years, poor ECOG PS, raised LDH, involvement of extranodal sites (stomach, kidney, adrenals and central nervous system) were associated with poor overall survival on multivariate analysis. Conclusions: This is one of the largest studies from India. Non GCB subtype was found to be associated with inferior EFS. Non R-CHOP regimen and high IPI were associated with inferior survival.
脑分水岭梗死34例
Authors: 张立才, 沙俊莹, 胡伟, 吕国栋, 赵绪珍
Journal: BMJ (2004)

脑分水岭梗死(cerebral watershed infarction,CWI)指脑内相邻较大血管供血区之间即边缘带发生局限性缺血,出现相应神经功能障碍.我科自1994～2001年CT确诊CWI 34 例,分析如下。
多发性骨髓瘤无分泌型转为轻链型一例并文献复习
Authors: 李旸, 李迎春, 王慧涵, 张国君, 胡荣, 刘卓刚
Journal: BMJ (2011)

多发性骨髓瘤(MM)是一种血液系统常见的恶性肿瘤,由于血液中的浆细胞克隆性增生,导致多器官损害,患者最终出现骨质破坏、贫血、肾功能不全、高钙血症以及易发感染等.根据骨髓瘤细胞是否分泌和分泌的单克隆免疫球蛋白类型的不同,可将多发性骨髓瘤分为8个类型:IgG、IgA、轻链型、IgD、IgE、IgM、双克隆或多克隆型、不分泌型.不分泌型骨髓瘤(NSMM)是MM的罕见类型,发病率约为骨髓瘤的1%～5%[1],以血和(或)尿中没有单克隆免疫球蛋白存在为特点[2].现报道一例NSMM患者经过2年的不分泌期之后,随疾病的进展开始合成和分泌大量单克隆免疫球蛋白λ轻链。
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
Authors: Ralph Zinner, Rita Axelrod, Charalambos C Solomides, Scott Cowan, Benjamin Leiby, Avnish K Bhatia, Mark L. Sundermeyer, D. Craig Hooper, Larry Harshyne, Grace L. Lu-Yao, Belen C Quereda-Bernabeu, Sung C Whang, Suzanne C OHara, Daniel C Vernau, Maria Werner-Wasik, Bo Lu, Jennifer M Johnson, Walter C Scott, Athanassios Argiris, Nathaniel R. Evans
Journal: Journal of Clinical Oncology (2020)

9051 Background: Patients (pts) with resectable stage IB (≥4cm)-IIIA non-small-cell lung cancer (NSCLC) derive modest overall survival benefit with neoadjuvant or postoperative adjuvant chemotherapy. Neoadjuvant therapy can speed the discovery of promising regimens by using pathologic response as a surrogate for OS. Major pathologic response (MPR), defined as &lt; 10% viable tumor, was strongly associated with improved OS. PD-(L)1 checkpoint inhibitors in combination with chemotherapy are standard of care in advanced NSCLC. We hypothesize that the addition of N to neoadjuvant CP or CG will increase the MPR rate compared to historical controls. Methods: This is an investigator-initiated trial for pts with newly diagnosed AJCC 8 th stage IB (≥4cm)-IIIA squamous or non-squamous EGFR/ALK WT NSCLC with a plan to have surgery. Pts receive 3 courses of N 360mg IV q 3w added to C 75mg/m2 IV q 3w plus P 500 mg/m 2 IV q 3wks or G 1250mg/m 2 IV d1, d8 with surgery 3 wks after the last dose. The primary objective is MPR. To estimate pathologic response, the resected pathology specimens are cut &gt;1 section/cm. Using the Aperio Digital scanning system©, slides were imaged, and then annotated by at least 2 pathologists for viable tumor vs. treatment effect with respective areas then automatically calculated and percentage of viable tumor calculated. Our primary endpoint will be reached if 10/34 (29%) planned pts have at least an MPR. Results: From 6/2018-8/2019, 13 pts were enrolled all of whom had surgery. Median age was 69 (49-80), 38% women, 31% nonsquamous, 54% stage IIIA, and 77% PD-L1 positive (≥1%, SP263). Pre-surgical grade 3 toxicity occurred in 2/13 pts, one of whom was changed to carboplatin for courses 2 and 3. Grade 3 toxicities were neutropenia (2/13), anemia (1/13), and renal (1/13). One pt. developed hypothyroidism 4 mos after surgery. One pt died 6 weeks after surgery from complications unrelated to study drugs. Our primary endpoint was met; 11/13 (85%), had at least an MPR with 6/13 (46%) and 5/13 (38%) having an MPR and pCR respectively. Radiologic response rate was 46% (PR 5, CR 1). Pts with either PD-L1+ or PD-L1- had MPRs. With a median follow-up of 10 months there are no recurrences. Conclusions: The combination of nivolumab added to platinum doublets was well tolerated. The primary endpoint of MPR in at least 10/34 pts was surpassed with MPR or pCR in 11/13 pts post-surgery. MPR was seen independent of PD-L1 score. Exploratory outcomes assessing markers of immune bias in tumor tissue and plasma are in process. Clinical trial information: NCT03366766.
A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Authors: Lara Dunn, Alan Loh Ho, Juliana Eng, Loren S. Michel, James Vincent Fetten, Elizabeth Warner, Anuja Kriplani, Wanqing Iris Zhi, Kenneth K. Ng, Sofia Haque, David G. Pfister, Eric Jeffrey Sherman
Journal: Journal of Clinical Oncology (2020)

6541 Background: Despite overexpression of EGFR in HNSCC, cetuximab monotherapy has limited benefit. Fibroblast growth factor receptor (FGFR) signaling is a known resistance mechanism to EGFR inhibition. Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor (RTKI) and has unique activity against FGFR 1,2,3, and 4. We are evaluating inhibition of EGFR and RTKs including FGFR through the combination of cetuximab and lenvatinib in patients (pts) with R/M HNSCC. Methods: In this phase I/Ib, single-institution study, pts with measurable disease per RECIST v1.1 that is incurable with surgery and radiation are eligible regardless of prior cetuximab therapy. The dose de-escalation phase included pts with HNSCC and cutaneous squamous cell carcinoma (cSCC) treated with standard cetuximab dosing and lenvatinib in 3 potential dose levels (DL): (0) 24mg, (-1) 20mg, (-2) 14mg oral daily in a standard 3+3 design. The primary objective was to determine the MTD of lenvatinib in combination with cetuximab. The expansion phase included an additional 5 pts with HNSCC treated at the MTD. Exploratory endpoints include ORR and PFS in HNSCC pts treated at the MTD. Results: 12 evaluable pts were treated on the dose de-escalation phase. There were no DLTs on DL 0; however, 3/6 pts were removed immediately following the 28-day DLT period due to toxicity that included extensive thrombotic events and athlerosclerotic disease. On DL -1, 0/6 pts (5 HNSCC/1 cSCC) had a DLT establishing lenvatinib 20mg daily as the MTD. 7 pts were enrolled onto the expansion phase; 4 are currently evaluable for response and 2 are unevaluable because of withdrawal due to a cetuximab reaction and required surgery. Of the 9 evaluable HNSCC pts treated with lenvatinib 20mg daily, 6 pts had a PR with a 67% ORR. For the 8 pts who have completed treatment, the median PFS is 3.6 months (range 1.6-10.4). Grade 3 AEs regardless of attribution included hypertension (3), oral mucositis (3) and oral cavity fistula (1). The most common AEs were acneiform rash (7), fatigue (6), and hypertension/hypothyroidism/oral mucositis (5 each). Conclusions: The MTD of lenvatinib 20mg daily with cetuximab appears to be active in R/M HSNCC with an impressive preliminary ORR, warranting further evaluation of the efficacy of this combination. Clinical trial information: NCT03524326 .
检测可溶性上皮细胞钙黏附蛋白在鉴别良恶性胸腔积液中的意义
Authors: 李儒佑, 杜黎明, 冯六连, 李清泉
Journal: BMJ (2006)

收集2003年7月至2005年7月住院患者的胸腔积液70份,其中癌性30份,结核性30份,漏出液10份,用酶联免疫法分别检测积液中的可溶性上皮细胞钙黏附蛋白浓度.结果显示,可溶性上皮细胞钙黏附蛋白浓度在渗出液中明显高于漏出液,在恶性胸腔积液中明显高于结核性胸腔积液,两者差异有统计学意义.表明检测可溶性上皮细胞钙黏附蛋白浓度在胸腔积液鉴别诊断中有很大的临床意义。